Although IL-17 has been proposed as a key mechanism for destruction of beta cells in type 1 diabetes during the past two decades, this study is the first pivotal trial performed to investigate potential beneficial effects of inhibiting IL-17 in people with newly diagnosed type 1 diabetes. Here, IL17A is linked to type 1 diabetes mellitus.